CN114650819A - 用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他 - Google Patents

用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他 Download PDF

Info

Publication number
CN114650819A
CN114650819A CN202080065098.2A CN202080065098A CN114650819A CN 114650819 A CN114650819 A CN 114650819A CN 202080065098 A CN202080065098 A CN 202080065098A CN 114650819 A CN114650819 A CN 114650819A
Authority
CN
China
Prior art keywords
subject
gvhd
pharmaceutically acceptable
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080065098.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·帕金
A·宋
S·Z·帕夫莱蒂
A·艾米
N·G·霍尔兹曼
C·J·皮尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meleo Biopharmaceutical No4 Co ltd
Duke University
United States Department of Health and Human Services
Original Assignee
Meleo Biopharmaceutical No4 Co ltd
Duke University
National Cancer Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meleo Biopharmaceutical No4 Co ltd, Duke University, National Cancer Institute filed Critical Meleo Biopharmaceutical No4 Co ltd
Publication of CN114650819A publication Critical patent/CN114650819A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080065098.2A 2019-09-17 2020-09-17 用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他 Pending CN114650819A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901638P 2019-09-17 2019-09-17
US62/901,638 2019-09-17
PCT/EP2020/075948 WO2021053058A1 (en) 2019-09-17 2020-09-17 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease

Publications (1)

Publication Number Publication Date
CN114650819A true CN114650819A (zh) 2022-06-21

Family

ID=72560598

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080065098.2A Pending CN114650819A (zh) 2019-09-17 2020-09-17 用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他

Country Status (10)

Country Link
US (1) US20220354833A1 (cg-RX-API-DMAC10.html)
EP (1) EP4031138A1 (cg-RX-API-DMAC10.html)
JP (1) JP7672641B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220079527A (cg-RX-API-DMAC10.html)
CN (1) CN114650819A (cg-RX-API-DMAC10.html)
AU (1) AU2020349353A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022004861A2 (cg-RX-API-DMAC10.html)
CA (1) CA3154761A1 (cg-RX-API-DMAC10.html)
IL (1) IL290991A (cg-RX-API-DMAC10.html)
WO (1) WO2021053058A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10894960B2 (en) 2016-08-30 2021-01-19 Children's Hospital Medical Center Compositions and methods for nucleic acid transfer
US12411144B2 (en) 2017-03-22 2025-09-09 Children's Hospital Medical Center Compositions and methods for treatment of lung function
US12618855B2 (en) 2019-10-08 2026-05-05 Children's Hospital Medical Center Serum protein biomarker panel for idiopathic pulmonary fibrosis
HUE064089T2 (hu) * 2020-04-16 2024-02-28 Mereo Biopharma 4 Ltd Alvelesztat neutrofil elasztáz inhibitort alkalmazó módszerek alfa-1-antitripszin hiány által közvetített légzõszervi megbetegedés kezelésére
AU2022373971A1 (en) 2021-10-20 2024-04-04 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis
WO2023212288A1 (en) * 2022-04-28 2023-11-02 Children's Hospital Medical Center Methods for improving outcomes for hematopoietic cell transplant recipients at risk for bronchiolitis obliterans syndrome
GB202319953D0 (en) * 2023-12-22 2024-02-07 Mereo Biopharma 4 Ltd Tablet formulations involving alvelestat

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674708A (en) 1989-06-23 1997-10-07 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having elastase inhibitory activity
DE69233760D1 (de) 1991-03-01 2009-06-25 Dyax Corp Inhibitoren der menschlichen Elastase von Neutrophilen
AU655301B2 (en) 1991-05-23 1994-12-15 Merrell Pharmaceuticals Inc. Inhibitors of cathepsin G and elastase for preventing connective tissue degradation
US5216022A (en) 1991-12-19 1993-06-01 Cortech, Inc. Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophil elastase
GB9307555D0 (en) 1992-04-16 1993-06-02 Zeneca Ltd Heterocyclic compounds
US5486529A (en) 1992-04-16 1996-01-23 Zeneca Limited Certain pyridyl ketones for treating diseases involving leukocyte elastase
DE69314169T2 (de) 1992-04-16 1998-01-15 Zeneca Ltd Peptide mit eine alphaaminoboronaire gruppe and ihre verwendung als elastasehemmer
US5441960A (en) 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
EP0636144A1 (en) 1992-04-16 1995-02-01 Zeneca Limited Alpha-aminoboronic acid peptides and their use as elastase inhibitors
GB9211783D0 (en) 1992-06-04 1992-07-15 Ici Plc Amide derivatives
GB9214053D0 (en) 1992-07-02 1992-08-12 Ici Plc Heterocyclic amides
GB9402680D0 (en) 1994-02-11 1994-04-06 Zeneca Ltd Pyrrolidine derivatives
AU690986B2 (en) 1994-06-02 1998-05-07 Merrell Pharmaceuticals Inc. Perfluoroalkyl ketone inhibitors of elastase and processes for making the same
KR100347285B1 (ko) 1994-06-02 2003-01-15 아벤티스 파마슈티칼스 인크. 신규의엘라스타제저해제
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
GB9502152D0 (en) 1995-02-03 1995-03-29 Zeneca Ltd Proline derivatives
IL125859A0 (en) 1996-03-28 1999-04-11 Glaxo Group Ltd Pyrrolopyrrolone derivatives useful as inhibitors of neutrophil elastase
AU726406B2 (en) 1996-04-12 2000-11-09 Regents Of The University Of Michigan, The Mutant plasminogen activator-inhibitor type 1 (PAI-1) and uses thereof
GB9719187D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
PE107899A1 (es) 1997-09-09 1999-11-17 Glaxo Group Ltd Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
KR20010078724A (ko) 1998-06-03 2001-08-21 존 더블류. 갈루치 2세 세린 프로테아제 저해제로서의 인돌 및테트라히드로이소퀴놀린을 함유하는 α-케토 옥사디아졸
US6255453B1 (en) 1998-06-03 2001-07-03 Cortech, Inc. Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors
US20030069187A1 (en) 2001-10-05 2003-04-10 Rao Srinivasa K. Elastase inhibitors
US20030119073A1 (en) 2001-12-21 2003-06-26 Stephen Quirk Sensors and methods of detection for proteinase enzymes
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302324D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
JP4825195B2 (ja) 2004-02-26 2011-11-30 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト １，４−ジアリール−ジヒドロピリミジン−２オン化合物およびヒト好中球エラスターゼ阻害剤としてのそれらの使用
ES2394177T3 (es) 2004-02-26 2013-01-23 Bayer Intellectual Property Gmbh 1,4-diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos
WO2006070012A1 (en) 2004-12-30 2006-07-06 Ingenium Pharmaceuticals Ag Agents useful in treating inflammatory bowel disease
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
GB0605469D0 (en) 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
DK2024367T3 (da) 2006-05-04 2011-01-03 Pulmagen Therapeutics Inflammation Ltd Tetrahydropyrrolopyrimidindioner og deres anvendelse som inhibitorer af human neutrofil elastase
WO2009013444A1 (en) 2007-07-25 2009-01-29 Argenta Discovery Limited Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
EP2019837B1 (en) 2006-05-23 2011-03-23 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2027143A2 (en) 2006-05-23 2009-02-25 Irm Llc Compounds and compositions as channel activating protease inhibitors
ES2293832B1 (es) 2006-07-17 2009-05-04 Cargoflet S.A. Sistema de transporte masivo de gas natural a alta presion por via maritima.
US20110003858A1 (en) 2006-09-04 2011-01-06 Bergstroem Lena Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
MX2009002960A (es) 2006-09-21 2009-06-26 Activx Biosciences Inc Inhibidores de serina hidrolasa.
AU2007342223B2 (en) 2007-01-10 2011-02-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
CA2677487A1 (en) 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors
WO2008104752A1 (en) 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
WO2009037413A1 (en) 2007-09-19 2009-03-26 Argenta Discovery Limited Dimers of 5- [ (4-cyanophenyl) sulfinyl] -6-methyl-2-oxo-1- [3- (trifluoromethyl)phenyl] -1,2-dihydropyridine-3-carboxamide as inhibitors of human neutrophil elastase for treating respiratory diseases
WO2009058076A1 (en) 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
WO2009061271A1 (en) 2007-11-06 2009-05-14 Astrazeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
WO2009060206A1 (en) 2007-11-07 2009-05-14 Argenta Discovery Limited 3,4,6,7-tetrahydro-1h-pyrrolo[3,4-d]pyrimidine-2,5-diones and their therapeutic use
WO2009060158A1 (en) 2007-11-07 2009-05-14 Argenta Discovery Limited 4- (4-cyanophenyl) -1- (3-trifluoromethylphenyl) -3,4, 6, 7-tetrahydro-1h-pyrrolo [3, 4- d] pyrimidine-2, 5-dione derivatives and their use as human neutrophil elastase inhibitors
GB0817429D0 (en) 2008-09-23 2008-10-29 Argenta Discovery Ltd Enzyme inhibitors
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
AU2010302420B2 (en) 2009-10-02 2013-07-04 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
US20110212181A1 (en) 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
GB201004179D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
GB201004178D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
EP2766366B1 (en) 2011-09-14 2016-11-09 Chiesi Farmaceutici S.p.A. Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhbitors
WO2013084199A1 (en) 2011-12-07 2013-06-13 Universidade De Lisboa Boron heterocycles as new inhibitors of human neutrophil elastase
JP2015517469A (ja) 2012-05-01 2015-06-22 デユーク・ユニバーシテイ 移植片拒絶のバイオマーカーとしてのヘパラン硫酸の組成物および方法
RU2638537C2 (ru) 2012-07-12 2017-12-14 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Ингибирование ферментов
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140221335A1 (en) 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
RU2016123379A (ru) 2013-12-16 2017-12-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Тетрагидротриазолопиримидиновые соединения в качестве ингибиторов нейтрофильной эластазы человека
JP6499182B2 (ja) 2013-12-27 2019-04-10 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ 選択的エラスターゼ阻害剤としてのβ−ヘアピンペプチド模倣体
LT3087094T (lt) 2013-12-27 2022-09-26 Spexis Ag Beta plaukų segtuko struktūros peptidų mimetikai, kaip selektyvūs elastazės slopikliai
US9221807B2 (en) 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9290457B2 (en) 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9458113B2 (en) 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2016020070A1 (en) 2014-08-05 2016-02-11 Gerard Voerman Mutants of leech derived neutrophil elastase inhibitors and uses thereof
WO2016050835A2 (en) 2014-10-02 2016-04-07 Ruprecht-Karls-Universität Heidelberg Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component
US9890169B2 (en) 2015-12-14 2018-02-13 Chiesi Farmaceutici S.P.A. Triazolinone compounds as HNE inhibitors
JP6990663B2 (ja) 2016-05-31 2022-01-13 シエッシ ファーマスーティシ エス．ピー．エー． ヒト好中球エラスターゼ阻害剤としてのイミダゾロン化合物

Also Published As

Publication number Publication date
JP7672641B2 (ja) 2025-05-08
EP4031138A1 (en) 2022-07-27
KR20220079527A (ko) 2022-06-13
IL290991A (en) 2022-05-01
WO2021053058A1 (en) 2021-03-25
AU2020349353A1 (en) 2022-04-14
JP2023500182A (ja) 2023-01-05
BR112022004861A2 (pt) 2022-06-07
CA3154761A1 (en) 2021-03-25
US20220354833A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
JP7672641B2 (ja) 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット
US11517572B2 (en) Killing senescent cells and treating senescence-associated conditions using a SRC inhibitor and a flavonoid
US20250276066A1 (en) Methods, compositions and compounds for treating age-related diseases and conditions
ES2476368T3 (es) Tratamiento de la artritis reumatoide con una combinación de laquinimod y metotrexato
KR20180126497A (ko) 치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법
CA2998509A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
CN117180280A (zh) 赖氨酰氧化酶样2抑制剂的用途
TWI602567B (zh) 磷脂醯肌醇－３－激酶（ｐｉ３ｋ）抑制劑及ｍｔｏｒ抑制劑之組合
JP2024178420A (ja) 多発性硬化症を治療するためのｌｏｕ０６４
TW201622728A (zh) 全身紅斑性狼瘡之治療
JP2018127487A (ja) 同種移植片拒絶反応を抑制する方法
AU2021283886A1 (en) Dihomo-gamma linolenic acid (DGLA) is a novel senolytic
TWI836022B (zh) 治療纖維化之方法
WO2022161364A1 (zh) 通路调节剂、含其的药物组合物、其用途和采用其的治疗方法
WO2022173334A2 (en) Methods, compositions and compounds for treating age-related diseases and conditions
Flowers Progress in the management of chronic GVHD insights into novel therapies to treat and manage GVHD lasting longer than 12 Months
WO2017087318A1 (en) Treatment of autoimmune disease
US20240382472A1 (en) Neutrophil elastase inhibitors for use in the treatment of fibrosis
JP2025516366A (ja) 同種移植拒絶反応の治療方法
HK40035915A (en) Treatment of autoimmune disease
HK1238150A1 (en) Treatment of autoimmune disease
HK1232801A1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
HK1232801B (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20230721

Address after: Great Britain London

Applicant after: Meleo biopharmaceutical No.4 Co.,Ltd.

Applicant after: DUKE University

Applicant after: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

Address before: Great Britain London

Applicant before: Meleo biopharmaceutical No.4 Co.,Ltd.

Applicant before: DUKE University

Applicant before: National Cancer Institute

TA01 Transfer of patent application right